Skip to main navigation

Investor Navigation

Overview
News & Events
- Press Releases
- Events & Presentations
Stock Information
Financials
- SEC Filings
Governance
IR Resources

Press Releases

Year

06 Nov '2024

Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results

23 Oct '2024

Context Therapeutics to Participate in Upcoming Investor Conferences in November

16 Oct '2024

Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

23 Sep '2024

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

04 Sep '2024

Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors

07 Aug '2024

Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results

01 Aug '2024

Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations

10 Jul '2024

Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95

08 May '2024

Context Therapeutics Reports First Quarter 2024 Operating and Financial Results

02 May '2024

Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 13

Investor Tools

Print Page
RSS Feeds
Search

Request Email Alerts

© 2024 Context Therapeutics Inc. All rights reserved.